Kushtrim Kryeziu

  • Project group leader; Researcher; PhD
  • +47 22781737

ORCID: 0000-0002-6633-4818

Biosketch

Molecular cell biologist with expertise in establishing patient-derived tumor organoid (PDO) models and executing mechanistic and functional studies integrated with genomics. My research focuses on understanding tumor heterogeneity and identifying personalized cancer therapies to improve patient outcomes.

Current Position

  • Project group leader in functional precision oncology, Oslo University Hospital (OUH), Department of Molecular Oncology, Norway

Education

  • 2016: PhD in Malignant Diseases: Medical University of Vienna, Austria
  • 2012: Mag.rer.nat in Genetics and Microbiology, University of Vienna, Austria

Research interests

  • Patient-derived tumor organoids (PDOs): Developing and characterizing these models to understand cancer biology and drug response.
  • Personalized cancer therapy: Using PDOs to predict individual patients´ response to specific treatments.
  • PARP inhibitor efficacy in colorectal cancer: Investigating and improving the effectiveness of this drug class in treating colorectal cancer.
  • Mechanisms of drug resistance: Understanding how tumors develop resistance to treatment, including both intrinsic and acquired mechanisms.

Fellowships and Awards

  • 2023: Early Career Award, Oslo University Hospital
  • 2022: Researcher of the Year, Institute for Cancer Research and the Norwegian Radium Hospital Legacy, OUH
  • 2022: BBA - Reviews on Cancer, selected journal front cover for the 2022 calendar year
  • 2016: Marie Skłodowska-Curie fellowship for developing talents (Scientia Fellows), European Commission and the University of Oslo

Funding

  • 2025-2029: RESCUE: cues to overcome treatment resistance in colorectal cancer. Norwegian Cancer Society
  • 2024-2027: Unleashing the potential of PARP inhibitors against colorectal cancer. South-Eastern Norway Regional Health Authorities
  • 2024: Co-culture assay for modeling the activity of immune checkpoint inhibitors in colorectal cancer, Familien Blix Fond
  • 2016-2018: Marie Skłodowska-Curie mobility grant, European Commission and the University of Oslo

Invited presentations at national and international scientific meetings

  • 2024: EHA-SfPM Precision Medicine Meeting: Bridging between functional and genomic precision medicine, Copenhagen, Denmark. “Functional precision oncology for the patients with metastatic colorectal cancer”
  • 2024: Norway Life Science 2024 (Microphysiological systems, organoids and organ on a chip technology, NOR_MPS symposium), Oslo. “Heterogeneity of tumor organoids derived from patients with colorectal cancer liver metastases”
  • 2023: EACR-OECI Molecular Pathology Approach to Cancer, Bergamo, Italy. Oral presentation: “Immunohistopathology of organoids derived from multifocal colorectal cancer liver metastases“.
  • 2022: The 7th international Conference on Cancer Research & Drug Development, Baltimore, USA. “Ex vivo treatment modeling of metastatic colorectal cancers in the context of tumor heterogeneity“.
  • 2018: American Association for Cancer Research, Special Conference on Intestinal stem cells and colon cancer: Biology to Therapy, Washington, DC, USA. Oral presentation: “Ex vivo pharmacogenomic heterogeneity of colorectal liver metastases”.

Public engagement

Complete publication list

 
Scroll to top